ArticleMaterials today. Bio2025
Umbilical cord blood-derived exosomes deliver miR-182-5p to Therapeutically target the MYD88/NF-κB signaling pathway in rat peri-implantitis.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Loss of EGFR activity in skeletal stem/progenitor cells is associated with impaired fracture healing in aged mice.Bioactive materials · 2027Article
- PRDX2 Mediates the Neuroprotective Role of Umbilical Cord Blood Exosomes via the CYP2J2/8,9-EET Pathway in Models of Parkinson's Disease.Molecular neurobiology · 2026Article
- Extracellular Vesicles as Orchestrators of Osteoimmunomodulation in Peri-Implantitis: Implications for Bone Regeneration.Clinical implant dentistry and related research · 2026Review
- Research advances in early diagnosis and treatment strategies for peri-implantitis: from microecology to regenerative therapy.Frontiers in cellular and infection microbiology · 2026Review
- Plant Exosome-Loaded Intelligent Hydrogels for Osteoporotic Bone Regeneration: Mechanisms and Applications.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peri-implantitis (PI) is a major cause of implant restoration failure, necessitating therapeutic strategies that integrate bone regeneration and anti-inflammatory effects. Despite advances in treatment, no existing agents simultaneously address both objectives. Exosomes (Exos), as key mediators of intercellular communication, have demonstrated dual anti-inflammatory and osteogenic capacities through microRNA (miRNA) delivery; however, their potential in PI therapy remains unexplored. This study evaluates the therapeutic efficacy of a composite hydrogel loaded with human umbilical cord blood-derived exosomes (UCB-Exos) in PI treatment, focusing on its dual anti-inflammatory and bone-regenerative functions, and elucidates the underlying molecular mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.